CRISPR Therapeutics CRSP Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's increase (decrease) in prepaid expense and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's increase (decrease) in prepaid expense and other assets?
- CRISPR Therapeutics (CRSP) reported increase (decrease) in prepaid expense and other assets of $247K in Q1 2026.
- How has CRISPR Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
- CRISPR Therapeutics's increase (decrease) in prepaid expense and other assets decreased by 61.0% year-over-year, from $634K to $247K.
- What is the long-term trend for CRISPR Therapeutics's increase (decrease) in prepaid expense and other assets?
- Over 2 years (2023 to 2025), CRISPR Therapeutics's increase (decrease) in prepaid expense and other assets has grown at a -62.1% compound annual growth rate (CAGR), from -$23.22M to -$3.34M.
- What does increase (decrease) in prepaid expense and other assets mean?
- This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.